回顾性、多中心倾向评分匹配（PMS）分析，旨在探讨贝伐珠单抗联合化疗治疗策略对既往接受聚 ADP-核糖聚合酶抑制剂治疗的复发性上皮性卵巢癌（EOC）患者的有效性和安全性(PARPis)。共有 250 名卵巢癌 (OC) 患者在 4 个医疗中心接受 PARPi 联合或不联合贝伐单抗化疗后复发。对于两种治疗，均采用 Kaplan-Meier 分析和 Cox 回归来比较 PFS。 在 250 名患者的多变量分析中，化疗中加入贝伐珠单抗显示 PFS 显着增强（风险比 [HR]=0.49；95% 置信区间） [CI]=0.34-0.72；p<0.001)。 PSM 分析后，55 名患者被纳入 A 组（贝伐珠单抗联合化疗），55 名患者被纳入 B 组（单独化疗方案）。两种方案之间的 PFS 存在统计学显着性差异（HR=0.62；95% CI=0.40-0.97；p=0.036），表明贝伐珠单抗联合化疗方案具有优越的临床获益。 A 组的中位 PFS 为 11 个月，B 组为 9 个月。无 RCRS 患者（HR=0.50；95% CI=0.30-0.82）和铂类耐药亚组（HR=0.31）之间的 PFS 存在显着差异。 ; 95% CI=0.14-0.68)。 A组3-4级不良反应比B组更常见。此外，仅A组报告了严重高血压和肠穿孔的病例。对于诊断为EOC的患者，PARPi后化疗联合贝伐珠单抗方案复发。与更好的 PFS 相关。© 2025。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

A retrospective, multi-center propensity score-matched (PMS) analysis was conducted to investigate the efficacy and safety of the treatment strategy that combines bevacizumab and chemotherapy for patients with relapsed epithelial ovarian cancer (EOC) who previously received poly ADP-ribose polymerase inhibitors (PARPis).A total of 250 ovarian cancer (OC) patients relapsed after PARPi received chemotherapy with or without bevacizumab at 4 medical centers were enrolled in the study. For both treatments, Kaplan-Meier analysis and Cox regression were used to compare PFS.In the multivariable analysis of 250 patients, the incorporation of bevacizumab into chemotherapy demonstrated a significant enhancement in PFS (hazard ratio [HR]=0.49; 95% confidence interval [CI]=0.34-0.72; p<0.001). Fifty-five patients were enrolled in Group A (bevacizumab combined with chemotherapy) and 55 were enrolled in Group B (chemotherapy alone regime) after PSM analysis. A statistically significant difference in PFS was observed between the 2 regimens (HR=0.62; 95% CI=0.40-0.97; p=0.036), suggesting that the bevacizumab combined with chemotherapy regimen confers superior clinical benefits. The median PFS was 11 months in Group A and 9 months in Group B. A significant variation was noted in PFS between patients without RCRS (HR=0.50; 95% CI=0.30-0.82) and the platinum-resistant subgroup (HR=0.31; 95% CI=0.14-0.68). Adverse effects of Grade 3-4 were more prevalent in Group A than in Group B. Additionally, instances of severe hypertension and bowel perforation were reported solely within Group A.In patients diagnosed with EOC relapsed after PARPi, the regime of chemotherapy combined with bevacizumab is associated with better PFS.© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.